COMMUNIQUÉS West-GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - April 2024

20/05/2024 - 22:54

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024

20/05/2024 - 22:54

Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

20/05/2024 - 22:16

AP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations Highlighted Post-hoc [...]

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

20/05/2024 - 22:05

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API [...]

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

20/05/2024 - 22:05

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its [...]

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia

20/05/2024 - 22:05

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose [...]

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

20/05/2024 - 22:03

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the [...]

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20/05/2024 - 22:01

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

20/05/2024 - 22:01

- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of [...]

Nurix Therapeutics Announces Board Chair Transition

20/05/2024 - 22:00

David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE [...]

“NASDAQ JAPAN IR EVENT” to Be Held at Nasdaq MarketSite on June 20, 2024

20/05/2024 - 21:00

Discover the appeal of Japanese companies listed in the U.S. NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM”, the [...]

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

20/05/2024 - 20:30

KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin Deficiency (AATD) [...]

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

20/05/2024 - 20:15

Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced [...]

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

20/05/2024 - 20:15

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive [...]

Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO

20/05/2024 - 20:15

Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent ® dans le traitement de la BPCO Les résultats de l’étude NOTUS confirment [...]

Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy

20/05/2024 - 17:35

ARC Therapy™ shown to be safe and effective in global pivotal trial* 90% of participants improved either strength or function of upper limbs* Improvement demonstrated in participants up to 34 years post-injury* 87% of [...]

U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”

20/05/2024 - 16:36

Olanzapine (ZYPREXA ® ) is an antipsychotic medication used to treat schizophrenia and bipolar disorder that is commonly used as anti-nausea off label medication. Olanzapine has been investigated for use as an [...]

Grin Garners Recognition From MedTech Breakthrough With “Best New Orthodontics Technology Solution”

20/05/2024 - 16:00

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies LOS ANGELES, May 20, 2024 (GLOBE NEWSWIRE) -- MedTech Breakthrough , an independent [...]

American Addiction Centers Names Greenhouse Treatment Center a Veterans Center of Excellence

20/05/2024 - 15:50

GRAND PRAIRIE, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- American Addiction Centers (AAC) has recognized Greenhouse Treatment Center as a Veterans Center of Excellence, highlighting its commitment to providing high- [...]